Brokers Issue Forecasts for Danaher Co.’s Q3 2024 Earnings (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Equities researchers at Leerink Partnrs lowered their Q3 2024 earnings per share estimates for shares of Danaher in a research report issued on Tuesday, April 23rd. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will post earnings per share of $1.70 for the quarter, down from their prior estimate of $1.87. The consensus estimate for Danaher’s current full-year earnings is $7.62 per share. Leerink Partnrs also issued estimates for Danaher’s Q4 2024 earnings at $2.42 EPS, FY2024 earnings at $7.60 EPS, Q1 2025 earnings at $2.25 EPS, FY2025 earnings at $8.70 EPS and FY2026 earnings at $9.63 EPS.

Several other research firms also recently commented on DHR. KeyCorp raised their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Robert W. Baird raised their target price on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday. Raymond James raised their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Price Performance

Shares of DHR stock opened at $245.82 on Thursday. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $182.04 billion, a P/E ratio of 41.66, a P/E/G ratio of 4.24 and a beta of 0.83. Danaher has a 12 month low of $182.09 and a 12 month high of $259.00. The stock has a 50 day moving average of $248.94 and a two-hundred day moving average of $230.88.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter last year, the company earned $2.36 EPS. The company’s quarterly revenue was down 2.6% on a year-over-year basis.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. Danaher’s payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 84,132 shares of company stock valued at $21,022,795. Company insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. ST Germain D J Co. Inc. boosted its position in shares of Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after buying an additional 41 shares during the period. Godsey & Gibb Inc. boosted its position in shares of Danaher by 3.0% during the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after buying an additional 42 shares during the period. Nicholas Hoffman & Company LLC. boosted its position in shares of Danaher by 2.3% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock worth $439,000 after buying an additional 43 shares during the period. Berger Financial Group Inc boosted its position in shares of Danaher by 1.7% during the fourth quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock worth $582,000 after buying an additional 43 shares during the period. Finally, Los Angeles Capital Management LLC boosted its position in shares of Danaher by 1.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock worth $803,000 after buying an additional 43 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.